Prevention of vincristine-induced peripheral neuropathy by genetic deletion of SARM1 in mice

Brain

Volumn 139, Issue 12, 2016, Pages 3092-3108

  Geisler, Stefanie ^a   Doan, Ryan A ^a   Strickland, Amy ^a   Huang, Xin ^a   Milbrandt, Jeffrey ^a   DiAntonio, Aaron ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Axonal degeneration; Chemotherapy induced peripheral neuropathy; CIPN; SARM1; Vincristine

Indexed keywords

PEPTIDES AND PROTEINS; STERILE ALPHA AND TIR MOTIF CONTAINING PROTEIN 1; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; ARMADILLO DOMAIN PROTEIN; CYTOSKELETON PROTEIN; SARM1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AXOTOMY; CONTROLLED STUDY; FEMALE; GENE DELETION; INTRACELLULAR SIGNALING; MALE; MECHANICAL HYPERALGESIA; MICROPHOTOGRAPHY; MOUSE; MOUSE MODEL; NERVE CONDUCTION; NERVE FIBER; NERVE FIBER DEGENERATION; NERVE POTENTIAL; NEUROPROTECTION; NONHUMAN; PERIPHERAL NERVE; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; SENSORY NERVE; SURAL NERVE; TRAUMATIC BRAIN INJURY; WILD TYPE; ANIMAL; AXON; C57BL MOUSE; CHEMICALLY INDUCED; DISEASE MODEL; GENETICS; KNOCKOUT MOUSE; PERIPHERAL NERVOUS SYSTEM DISEASES;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ARMADILLO DOMAIN PROTEINS; AXONS; CYTOSKELETAL PROTEINS; DISEASE MODELS, ANIMAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PERIPHERAL NERVOUS SYSTEM DISEASES; VINCRISTINE;

EID: 85010655795     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/aww251     Document Type: Article

References (69)

1. Araki T, Sasaki Y, Milbrandt J. Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 2004; 305: 1010-3.
2. Argyriou AA, Kyritsis AP, Makatsoris T, Kalofonos HP. Chemotherapy-induced peripheral neuropathy in adults: a comprehensive update of the literature. Cancer Manag Res 2014; 6: 135-47.
3. Authier N, Gillet J-P, Fialip J, Eschalier A, Coudore F. A new animal model of vincristine-induced nociceptive peripheral neuropathy. Neurotoxicology 2003; 24: 797-805.
4. Beirowski B, Adalbert R, Wagner D, Grumme DS, Addicks K, Ribchester RR, et al. The progressive nature of Wallerian degeneration in wild-type and slow Wallerian degeneration (WldS) nerves. BMC Neurosci 2005; 6: 1-27.
5. Boehmerle W, Huehnchen P, Peruzzaro S, Balkaya M, Endres M. Electrophysiological, behavioral and histological characterization of paclitaxel, cisplatin, vincristine and bortezomib-induced neuropathy in C57Bl/6 mice. Sci Rep 2014; 4: 6370.
6. Boyette-Davis JA, Cata JP, Driver LC, Novy DM, Bruel BM, Mooring DL, et al. Persistent chemoneuropathy in patients receiving the plant alkaloids paclitaxel and vincristine. Cancer Chemother Pharmacol 2013; 71: 619-26.
7. Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci 1970; 10: 107-31.
8. Bruna J, Alé A, Velasco R, Jaramillo J, Navarro X, Udina E. Evaluation of pre-existing neuropathy and bortezomib retreatment as risk factors to develop severe neuropathy in a mouse model. J Peripher Nerv Syst 2011; 16: 199-212.
9. Carozzi VA, Canta A, Chiorazzi A. Chemotherapy-induced peripheral neuropathy: What do we know about mechanisms? Neurosci Lett 2015; 596: 90-107.
10. Casey EB, Jellife AM, Le Quesne PM, Millett YL. Vincristine neuropathy. Clinical and electrophysiological observations. Brain 1973; 96: 69-86.
11. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53: 55-63.
12. Chaudhry V, Chaudhry M, Crawford TO, Simmons-O'Brien E, Griffin JW. Toxic neuropathy in patients with pre-existing neuropathy. Neurology 2003; 60: 337-40.
13. Chen CY, Lin CW, Chang CY, Jiang ST, Hsueh YP. Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology. J Cell Biol 2011; 193: 769-84.
14. Coleman MP, Conforti L, Buckmaster EA, Tarlton A, Ewing RM, Brown MC, et al. An 85-kb tandem triplication in the slow Wallerian degeneration (Wld(s)) mouse. Proc Natl Acad Sci USA 1998; 95: 9985-90.
15. Costa TC, Lopes M, Anjos AC, Zago MM. Chemotherapy-induced peripheral neuropathies: an integrative review of the literature. Rev Esc Enferm USP 2015; 49: 335-45.
16. De Jesus-Cortes H, Xu P, Drawbridge J, Estill SJ, Huntington P, Tran S, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci USA 2012; 109: 17010-5.
17. DeAngelis LM, Gnecco C, Taylor L, Warrell RP Jr. Evolution of neuropathy and myopathy during intensive vincristine/corticosteroid chemotherapy for non-Hodgkin's lymphoma. Cancer 1991; 67: 2241-6.
18. Diouf B, Crews KR, Lew G, Pei D, Cheng C, Bao J, et al. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia. JAMA 2015; 313: 815-23.
19. Dixon WJ. Efficient analysis of experimental observations. Annu Rev Pharmacol Toxicol 1980; 20: 441-62.
20. Ebenezer GJ, McArthur JC, Thomas D, Murinson B, Hauer P, Polydefkis M, et al. Denervation of skin in neuropathies: the sequence of axonal and Schwann cell changes in skin biopsies. Brain 2007; 130(Pt 10): 2703-14.
21. Ezendam NP, Pijlman B, Bhugwandass C, Pruijt JF, Mols F, Vos MC, et al. Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among ovarian cancer survivors: results from the population-based PROFILES registry. Gynecol Oncol 2014; 135: 510-7.
22. Gerdts J, Brace EJ, Sasaki Y, DiAntonio A, Milbrandt J. SARM1 activation triggers axon degeneration locally via NAD(+) destruction. Science 2015; 348: 453-7.
23. Gerdts J, Summers DW, Milbrandt J, DiAntonio A. Axon self-destruction: new links among SARM1, MAPKs, and NAD+ metabolism. Neuron 2016; 89: 449-60.
24. Gerdts J, Summers DW, Sasaki Y, DiAntonio A, Milbrandt J. Sarm1-mediated axon degeneration requires both SAM and TIR interactions. J Neurosci 2013; 33: 13569-80.
25. Gilley J, Coleman MP. Endogenous Nmnat2 is an essential survival factor for maintenance of healthy axons. PLoS Biol 2010; 8: e1000300.
26. Gilley J, Orsomando G, Nascimento-Ferreira I, Coleman MP. Absence of SARM1 rescues development and survival of NMNAT2-deficient axons. Cell Rep 2015; 10: 1974-81.
27. Gottschalk PG, Dyck PJ, Kiely JM. Vinca alkaloid neuropathy: nerve biopsy studies in rats and in man. Neurology 1968; 18: 875-82.
28. Guiheneuc P, Ginet J, Groleau JY, Rojouan J. Early phase of vincristine neuropathy in man. Electrophysiological evidence for a dying-back phenomenon, with transitory enhancement of spinal transmission of the monosynaptic reflex. J Neurol Sci 1980; 45: 355-66.
29. Haim N, Epelbaum R, Ben-Shahar M, Yarnitsky D, Simri W, Robinson E. Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer 1994; 73: 2515-9.
30. Henninger N, Bouley J, Sikoglu EM, An J, Moore CM, King JA, et al. Attenuated traumatic axonal injury and improved functional outcome after traumatic brain injury in mice lacking Sarm1. Brain 2016; 139(Pt 4): 1094-105.
31. Himes RH, Kersey RN, Heller-Bettinger I, Samson FE. Action of the vinca alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on microtubules in vitro. Cancer Res 1976; 36: 3798-802.
32. Jongen JL, Broijl A, Sonneveld P. Chemotherapy-induced peripheral neuropathies in hematological malignancies. J Neurooncol 2015; 121: 229-37.
33. Kamei J, Tamura N, Saitoh A. Possible involvement of the spinal nitric oxide/cGMP pathway in vincristine-induced painful neuropathy in mice. Pain 2005; 117: 112-20.
34. Kim Y, Zhou P, Qian L, Chuang JZ, Lee J, Li C, et al. MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med 2007; 204: 2063-74.
35. LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology 2013; 37: 231-9.
36. Lavoie Smith EM, Li L, Chiang C, Thomas K, Hutchinson RJ, Wells EM, et al. Patterns and severity of vincristine-induced peripheral neuropathy in children with acute lymphoblastic leukemia. J Peripher Nerv Syst 2015; 20: 37-46.
37. Liew E, Thyagu S, Atenafu EG, Alibhai SM, Brandwein JM. Quality of life following completion of treatment for adult acute lymphoblastic leukemia with a pediatric-based protocol. Leuk Res 2013; 37: 1632-5.
38. Lin CW, Hsueh YP. Sarm1, a neuronal inflammatory regulator, controls social interaction, associative memory and cognitive flexibility in mice. Brain Behav Immun 2014; 37: 142-51.
39. Lunn ER, Perry VH, Brown MC, Rosen H, Gordon S. Absence of Wallerian degeneration does not hinder regeneration in peripheral nerve. Eur J Neurosci 1989; 1: 27-33.
40. Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, et al. Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 2001; 4: 1199-206.
41. Massoll C, Mando W, Chintala SK. Excitotoxicity upregulates SARM1 protein expression and promotes Wallerian-like degeneration of retinal ganglion cells and their axons. Invest Ophthalmol Vis Sci 2013; 54: 2771-80.
42. Milde S, Gilley J, Coleman MP. Subcellular localization determines the stability and axon protective capacity of axon survival factor Nmnat2. PLoS Biol 2013; 11: e1001539.
43. Moress GR, D'Agostino AN, Jarcho LW. Neuropathy in lymphoblastic leukemia treated with vincristine. Arch Neurol 1967; 16: 377-84.
44. Ness KK, Jones KE, Smith WA, Spunt SL, Wilson CL, Armstrong GT, et al. Chemotherapy-related neuropathic symptoms and functional impairment in adult survivors of extracranial solid tumors of childhood: results from the St. Jude Lifetime Cohort Study. Arch Phys Med Rehabil 2013; 94: 1451-7.
45. Osterloh JM, Yang J, Rooney TM, Fox AN, Adalbert R, Powell EH, et al. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 2012; 337: 481-4.
46. Owellen RJ, Hartke CA, Dickerson RM, Hains FO. Inhibition of tubulin-microtubule polymerization by drugs of the Vinca alkaloid class. Cancer Res 1976; 36: 1499-502.
47. Reinders-Messelink HA, Van Weerden TW, Fock JM, Gidding CE, Vingerhoets HM, Schoemaker MM, et al. Mild axonal neuropathy of children during treatment for acute lymphoblastic leukaemia. Eur J Paediatr Neurol 2000; 4: 225-33.
48. Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Maeda T, Ozaki M, et al. Suppressive effect of imipramine on vincristine-induced mechanical allodynia in mice. Biol Pharm Bull 2009; 32: 1231-4.
49. Sandler SG, Tobin W, Henderson ES. Vincristine-induced neuropathy. A clinical study of fifty leukemic patients. Neurology 1969; 19: 367-74.
50. Shen Y, Zhang ZJ, Zhu MD, Jiang BC, Yang T, Gao YJ. Exogenous induction of HO-1 alleviates vincristine-induced neuropathic pain by reducing spinal glial activation in mice. Neurobiol Dis 2015; 79: 100-10.
51. Siau C, Xiao W, Bennett GJ. Paclitaxel- and vincristine-evoked painful peripheral neuropathies: loss of epidermal innervation and activation of Langerhans cells. Exp Neurol 2006; 201: 507-14.
52. Szretter KJ, Samuel MA, Gilfillan S, Fuchs A, Colonna M, Diamond MS. The immune adaptor molecule SARM modulates tumor necrosis factor alpha production and microglia activation in the brainstem and restricts West Nile Virus pathogenesis. J Virol 2009; 83: 9329-38.
53. Tanner KD, Levine JD, Topp KS. Microtubule disorientation and axonal swelling in unmyelinated sensory axons during vincristine-induced painful neuropathy in rat. J Comp Neurol 1998a; 424: 563-76.
54. Tanner KD, Reichling DB, Gear RW, Paul SM, Levine JD. Altered temporal pattern of evoked afferent activity in a rat model of vincristine-induced painful peripheral neuropathy. Neuroscience 2003; 118: 809-17.
55. Tanner KD, Reichling DB, Levine JD. Nociceptor hyper-responsiveness during vincristine-induced painful peripheral neuropathy in the rat. J Neurosci 1998b; 18: 6480-91.
56. Tesla R, Wolf HP, Xu P, Drawbridge J, Estill SJ, Huntington P, et al. Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2012; 109: 17016-21.
57. Thibault K, Rivals I, M'Dahoma S, Dubacq S, Pezet S, Calvino B. Structural and molecular alterations of primary afferent fibres in the spinal dorsal horn in vincristine-induced neuropathy in rat. J Mol Neurosci 2013; 51: 880-92.
58. Topp KS, Tanner KD, Levine JD. Damage to the cytoskeleton of large diameter sensory neurons and myelinated axons in vincristine-induced painful peripheral neuropathy in the rat. J Comp Neurol 2000; 424: 563-76.
59. Uceyler N, Braunsdorf S, Kunze E, Riediger N, Scheytt S, Divisova S, et al. Cellular infiltrates in skin and sural nerve of patients with polyneuropathies. Muscle Nerve 2016, Jul 7 Epub ahead of print.
60. Verstappen CC, Koeppen S, Heimans JJ, Huijgens PC, Scheulen ME, Strumberg D, et al. Dose- related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 2005; 64: 1076-7.
61. Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S, et al. P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell 2014; 158: 1324-34.
62. Wang JT, Medress ZA, Barres BA. Axon degeneration: molecular mechanisms of a self-destruction pathway. J Cell Biol 2012; 196: 7-18.
63. Wang MS, Davis AA, Culver DG, Glass JD. WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 2002; 52: 442-7.
64. Wang MS, Fang G, Culver DG, Davis AA, Rich MM, Glass JD. The WldS protein protects against axonal degeneration: A model of gene therapy for peripheral neuropathy. Ann Neurol 2001; 50: 773-9.
65. Weng HR, Cordella JV, Dougherty PM. Changes in sensory processing in the spinal dorsal horn accompany vincristine-induced hyperalgesia and allodynia. Pain 2003; 103: 131-8.
66. Wu G, Ringkamp M, Hartke TV, Murinson BB, Campbell JN, Griffin JW, et al. Early onset of spontaneous activity in uninjured C-fiber nociceptors after injury to neighboring nerve fibers. J Neurosci 2001; 21: RC140.
67. Wu G, Ringkamp M, Murinson BB, Pogatzki EM, Hartke TV, Weerahandi HM, et al. Degeneration of myelinated efferent fibers induces spontaneous activity in uninjured C-fiber afferents. J Neurosci 2002; 22: 7746-53.
68. Yang J, Wu Z, Renier N, Simon DJ, Uryu K, Park DS, et al. Pathological axonal death through a MAPK cascade that triggers a local energy deficit. Cell 2015; 160: 161-76.
69. Yin TC, Britt JK, De Jesus-Cortes H, Lu Y, Genova RM, Khan MZ, et al. P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep 2014; 8:1731-40.